Risk factors for postoperative myasthenia gravis in patients with thymoma without myasthenia gravis: A systematic

Mingbo Tang1, Yifeng Shao1, Junxue Dong2

  • 1Department of Thoracic Surgery, The First Hospital of Jilin University, Changchun, Jilin, China.

Frontiers in Oncology
|February 27, 2023
PubMed
Abstract

Insights

Postoperative myasthenia gravis (PMG) can occur in patients with thymoma without myasthenia gravis (MG). Key risk factors for PMG include preoperative acetylcholine receptor antibodies, open thymectomy, non-R0 resection, WHO type B thymoma, and postoperative inflammation.

Area of Science:

  • Medical research
  • Clinical oncology
  • Neurology

Background:

  • Thymoma, a primary tumor of the thymus, is often associated with myasthenia gravis (MG).
  • However, patients with thymoma but without pre-existing MG can develop it post-surgery, a condition termed postoperative myasthenia gravis (PMG).
  • Understanding PMG incidence and risk factors is crucial for patient management.

Approach:

  • A comprehensive meta-analysis was conducted, searching major databases (PubMed, EMBASE, Web of Science, CNKI, Wanfang).
  • Included studies focused on risk factors for PMG in non-MG thymoma patients.
  • Risk ratios (RR) and 95% confidence intervals (CI) were pooled using meta-analysis.

Key Points:

  • The meta-analysis included 13 cohorts with 2,448 patients, revealing an 8% incidence of PMG.
  • Significant risk factors identified for PMG include preoperative acetylcholine receptor antibody (AChR-Ab) seropositivity, open thymectomy, non-R0 resection, World Health Organization (WHO) type B thymoma, and postoperative inflammation.
  • Masaoka stage and sex were not significantly associated with PMG development.

Conclusions:

  • Patients with thymoma and no prior MG have a notable risk of developing PMG after surgery.
  • While thymectomy is standard, it does not entirely prevent MG onset.
  • Identifying and mitigating identified risk factors is essential for improving outcomes in thymoma patients.

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.1K
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.0K
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
21
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
13
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
535